Cargando…

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoering, Antje, Durie, Brian, Wang, Hongwei, Crowley, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705823/ https://www.ncbi.nlm.nih.gov/pubmed/28395525 http://dx.doi.org/10.2217/fon-2016-0504

Ejemplares similares

Statistical issues and challenges in immuno-oncology
por: Chen, Tai-Tsang
Publicado: (2013)

Immuno-Oncology Medicines: Policy Implications and Economic Considerations
por: Adunlin, Georges, et al.
Publicado: (2019)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials
por: Hu, Chen, et al.
Publicado: (2021)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
por: Durie, Brian G. M., et al.
Publicado: (2020)

Lifestyle considerations in multiple myeloma
por: Shapiro, Yael N., et al.
Publicado: (2021)

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
por: Van Ness, Brian, et al.
Publicado: (2008)

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2020)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Immuno-Oncology Essentials: An Overview
por: Hoffner, Brianna
Publicado: (2019)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
por: Ludwig, Heinz, et al.
Publicado: (2020)

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
por: Usmani, S., et al.
Publicado: (2022)

Ironing out exercise on immuno-oncological outcomes
por: Soh, Janjira, et al.
Publicado: (2022)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Clinical Considerations for Immunoparesis in Multiple Myeloma
por: Chahin, Michael, et al.
Publicado: (2022)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
por: Ji, Yan, et al.
Publicado: (2018)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
por: Heuck, C J, et al.
Publicado: (2014)

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
por: Srkalovic, Gordan, et al.
Publicado: (2014)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Immuno-oncology for B-cell lymphomas
por: Choi, Yoon Seok
Publicado: (2021)

Virus-Based Immuno-Oncology Models
por: Sitta, Juliana, et al.
Publicado: (2022)

Organoids as an Enabler of Precision Immuno-Oncology
por: Zhao, Junzhe, et al.
Publicado: (2023)

Single-Cell Analysis in Immuno-Oncology
por: Christodoulou, Maria-Ioanna, et al.
Publicado: (2023)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

Racing CARs to veterinary immuno-oncology
por: Cockey, James R., et al.
Publicado: (2023)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
por: Vanmeerbeek, Isaure, et al.
Publicado: (2020)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gmr5vidg793s3ia551so5jvkfa